Table 2.
Survival analysis for the overall population and according to first-line therapy (endocrine therapy or chemotherapy).
| Overall population | Patients treated with first line endocrine therapy | Patients treated with 1st line chemotherapy (+/− endocrine therapy) | ||||
|---|---|---|---|---|---|---|
| Adjusted HR [95% CI] | p | Adjusted HR [95% CI] | p | Adjusted HR [95% CI] | p | |
| Overall survival | ||||||
| gBRCAwt | 1 | 1 | 1 | |||
| gBRCAm | 1.26 [1.03–1.55] | 0.024 | 1.54 [1.03–2.32] | 0.037 | 1.12 [0.88–1.41] | 0.350 |
| gBRCA untested | 1.13 [1.03–1.25] | 0.010 | 1.25 [1.05–1.49] | 0.012 | 1.09 [0.98–1.23] | 0.125 |
| 1st line Progression-free survival | ||||||
| gBRCAwt | 1 | 1 | 1 | |||
| gBRCAm | 1.21 [1.03–1.41] | 0.017 | 1.58 [1.17–2.12] | 0.003 | 1.09 [0.90–1.31] | 0.379 |
| gBRCA untested | 1.02 [0.95–1.10] | 0.551 | 1.09 [0.97–1.24] | 0.149 | 0.98 [0.90–1.07] | 0.698 |
Statistically significant p-values are in bold.
The adjusted Hazard Ratios were estimated using a multivariable Cox model including gBRCA status as a time-varying variable.